



# WELCURE DRUGS & PHARMACEUTICALS LTD.

CIN: L24232DL1996PLC227773

Regd. Off.: Plot No. 55, Office No- 104 First Floor Vijay Block , Laxmi Nagar, East Delhi, Delhi-110092

Email: [welcuredrugs227@gmail.com](mailto:welcuredrugs227@gmail.com) Website: [www.welcuredrugs.com](http://www.welcuredrugs.com)

**Date: 8<sup>th</sup> April, 2024**

To,

The General Manager,  
Corporate Relationship Department,  
BSE Limited,  
Phiroz Jeejeebhoy Tower,  
Dalal Street, Mumbai — 400001,  
Maharashtra, India

**Reference : ISIN - INE331C01017 Scrip Code-524661; Symbol- WELCURE**

**Subject: Statement of Investor Grievances under Regulation 13 (3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015**

The statement of Investor Grievances pursuant to Regulation 13 (3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 as provided by our Registrar and Transfer Agent M/s Skyline Financial Services Private Limited for the quarter ended 31st March, 2024 is as follows:-

Pending at the beginning of the quarter	0
Received during the quarter	0
Disposed off during the quarter	0
Remaining unresolved at the end of the quarter	0

You are requested to take the same into your records and acknowledge.

Thanking you

Yours Faithfully

**FOR WELCURE DRUGS & PHARMACEUTICALS LTD.**



**ALTAF HUSSAIN SHAH**  
**MANAGING DIRECTOR AND CFO**  
**DIN- 10351528**

April 3, 2024

REF: SFSPL/QTR/March/2024

COMPANY SECRETARY

**WELCURE DRUGS & PHARMACEUTICALS LIMITED**

33/36 BASEMENT (BACK SIDE),  
WEST PATEL NAGAR NEAR RAM  
JASS GROUND, DELHI 11000B.

**Sub: Statement of Investor Complaints as per Regulation 13(3) of (LODR), 2015**

Dear Sir/Madam,

This is to inform you that our Company **WELCURE DRUGS & PHARMACEUTICALS LIMITED** having **CIN: L24232DL1996PLC227773** is registered on the SCORES platform of the SEBI in order to handle investor's complaints electronically.

As required under regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is the list of complaints received from complainants, complaints resolved as pending for consideration.

Number of investors complaints pending at the beginning of the quarter starting from 1st January, 2024	Complaints received during the Quarter From 1st January, 2024 To 31st March, 2024	Complaints disposed of during the Quarter From 1st January, 2024 To 31st March, 2024	Complaints remaining unresolved at the end of Quarter Ended on 31st March, 2024
NIL	NIL	NIL	NIL


Please find the details hereunder :-

S.No.	Received From	Pending at the end of last quarter	Received During the Quarter	Resolved	Total Pending
1	Directly from Investors	NIL	NIL	NIL	NIL
2	SEBI SCORES	NIL	NIL	NIL	NIL
3	Stock Exchanges	NIL	NIL	NIL	NIL
4	Other Sources (if Any)	NIL	NIL	NIL	NIL
5	Grand Total	NIL	NIL	NIL	NIL

We hereby certify that we have NIL pending complaints at our end for the period.

Thanking you,

**For Skyline Financial Services Pvt. Limited**

  
Vijay Kumar  
(Authorised Signatory)  
Investor Grievances Cell

